No data to show
XHKG
9995
Market cap3.32bUSD
May 09, Last price
38.80HKD
1D
0.00%
1Q
168.33%
IPO
-43.19%
Name
RemeGen Co Ltd
Chart & Performance
P/E
—
P/S
22.29
EPS
—
Div Yield, %
—
Shrs. gr., 5y
2.44%
Rev. gr., 5y
148.65%
Revenues
1.08b
+40.16%
Net income
-1.51b
L+51.45%
CFO
-1.50b
L+18.84%
Earnings
Aug 14, 2025
Profile
RemeGen Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologics for the treatment of autoimmune, oncology, and ophthalmic diseases with unmet medical needs in Mainland China and the United States. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. Its products in various stages of development include RC18, which is under phase III clinical trials for the treatment of neuromyelitis optica spectrum disorder and rheumatoid arthritis, and phase II clinical trials for the treatment of IgA nephritis, Sjögren's syndrome, multiple sclerosis, and myasthenia gravis; RC28, which has completed Phase 1 clinical trials for use in the treatment of wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy; RC98, a PD-L1 monoclonal antibody for the treatment of solid tumors and is under Phase I clinical trial; RC88, which is in Phase 1 clinical trials for use in the treatment of mesothelioma, bile duct carcinoma, pancreatic cancer, ovarian carcinoma, lung adenocarcinoma, and other solid tumors, as well as lung and urothelial cancer; and RC108 that is in Phase 1 clinical trials to treat various solid tumors. In addition, the company's products under pre-clinical development include RC118, RC138, RC148, RC158, RC168, RC178, RC188, and RC198 to treat various solid tumors; and RC208, RC218, and RC228 to treat ophthalmic diseases. RemeGen Co., Ltd. was incorporated in 2008 and is headquartered in Yantai, the People's Republic of China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | ||||||
Revenues | 1,076,130 40.16% | 767,775 -46.08% | ||||
Cost of revenue | 2,648,301 | 1,965,257 | ||||
Unusual Expense (Income) | ||||||
NOPBT | (1,572,171) | (1,197,482) | ||||
NOPBT Margin | ||||||
Operating Taxes | (993) | |||||
Tax Rate | ||||||
NOPAT | (1,572,171) | (1,196,489) | ||||
Net income | (1,511,229) 51.45% | (997,837) -461.20% | ||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | (65,160) | 2,530,614 | ||||
BB yield | 0.32% | -8.23% | ||||
| Debt | ||||||
Debt current | 344,720 | 60,154 | ||||
Long-term debt | 1,048,309 | 269,916 | ||||
Deferred revenue | 36,659 | 43,669 | ||||
Other long-term liabilities | ||||||
Net debt | 551,409 | (1,820,303) | ||||
| Cash flow | ||||||
Cash from operating activities | (1,501,829) | (1,263,689) | ||||
CAPEX | (852,757) | (757,517) | ||||
Cash from investing activities | (817,650) | (841,557) | ||||
Cash from financing activities | 978,307 | 2,426,949 | ||||
FCF | (2,364,180) | (2,436,951) | ||||
| Balance | ||||||
Cash | 743,393 | 2,069,180 | ||||
Long term investments | 98,227 | 81,193 | ||||
Excess cash | 787,813 | 2,111,984 | ||||
Stockholders' equity | (2,309,247) | 624,749 | ||||
Invested Capital | 7,043,158 | 4,549,571 | ||||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | 539,725 | 531,155 | ||||
Price | 37.45 -35.32% | 57.90 -20.14% | ||||
Market cap | 20,212,690 -34.28% | 30,753,849 -12.98% | ||||
EV | 20,764,099 | 28,933,546 | ||||
EBITDA | (1,331,892) | (1,011,111) | ||||
EV/EBITDA | ||||||
Interest | 23,091 | 6,757 | ||||
Interest/NOPBT | ||||||